The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner

Cancer Research

Volumn 62, Issue 15, 2002, Pages 4307-4315

  Chakravarti, Arnab ^a   Chakladar, Abhijit ^b   Delaney, Meaghan A ^a   Latham, Douglas E ^a   Loeffler, Jay S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN P42; PROTEIN P44; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN;

APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ANTAGONISM; DRUG EFFICACY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOMODULATION; INHIBITION KINETICS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0036681993     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
2. Randomized comparisons of radiotherapy and nitrosoumas for the treatment of malignant gliomas after surgery
3. Rubin two-arm RTOG trial (94-11) of bischloroethyl-nitrosurea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (>20 or < or = 20 cm. Respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients
4. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group Trial 9507
5. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma
6. The epidermal growth factor receptor as a target for therapy in breast carcinoma
7. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
8. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
9. The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation
10. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type 1 protein kinase A antisense oligonucleotide
11. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
12. Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death
13. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous cell carcinoma but not normal mucosal epithelial cells
14. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
15. Rowinsky pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
16. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
17. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
18. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody
19. Conversion of a radio-resistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells
20. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
21. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
22. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors
23. The epidermal growth factor receptor and its inhibition in cancer therapy
24. The EGF receptor as central transducer of heterologous signalling systems
25. Targeting signal transduction for disease therapy
26. Signal perception and transduction: The role of protein kinases
27. The AKT/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme
28. Epidermal growth factor-related peptides and their receptors in human malignancies
29. Akt. MAPK (Erk 1, 2) and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition
30. Linking extracellular survival signals and the apoptotic machinery
31. Transformation and altered signal transduction by a naturally occurring mutant EGF receptor
32. Shc regulates epidermal growth factor-induced activation of the JNK signaling pathway
33. p53-independent apoptosis: A mechanism of radiation-induced cell death of glioblastoma cells
34. The cell survival signal AKT is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells
35. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes
36. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal regulatory proteins (SIRPs)
37. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells
38. Tyrosine kinase inhibition: An approach to drug development
39. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
40. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
41. A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor
42. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic RAS signaling by inducing cytoplasmic accumulation of inactive RAS-RAF complexes
43. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
44. Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: Implications for combined modality therapy
45. Malignant glioma: Genetics and biology of a grave matter
46. Signal transduction pathways and their relevance in human astrocytoma
47. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects
48. Isotype-specific Ras-GTP levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of ras mutational status
49. Proliferation of human malignant astrocytomas is dependent on ras activation
50. Ras activation in astrocytomas and neurofibromas
51. RAS-mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines
52. The Ras radiation resistance pathway
53. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53
54. Transactivation-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway
55. Regulation of neuronal survival by the serine-threonine protein kinase Akt
56. Cellular survival: A play in three Akts
57. Role of AKT and c-jun N-terminal kinase 2 in apoptosis induced by interleukin-4 deprivation
58. Glycogen synthase kinase-3β activity is critical for neuronal death caused by inhibiting phosphatidyl 3-kinase or AKT but not for death caused by nerve growth factor withdrawal
59. Akt is a direct target of the phosphatidylinositol 3-kinase
60. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor-1
61. Antiapoptotic signaling by the insulin-like growth factor-I receptor, phosphatidylinositol 3-kinase, and AKT
62. Activation of AKT kinase inhibits apoptosis and changes in bcl-2 and bax expression induced by nitric oxide in primary hippocampal neurons
63. Akt and bcl-xl promote growth-factor-independent survival through distinct effects on mitochondrial physiology